Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALN-APOC3 in Adult Participants With Dyslipidemia
NCT06784349Phase 1Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Jan 2025
- Primary completion
- Feb 2026
- Modality
- Lipid-based Nanoparticles, Conjugated siRNA, Chemically Modified siRNA
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of ALN-APOC3 in dyslipidemia (5 arms), sponsored by Regeneron Pharmaceuticals. Primary endpoints: Incidence of Treatment Emergent Adverse Events at 44 weeks, Severity of Treatment Emergent Adverse Events at 44 weeks and 1 more. Started Jan 2025; status: completed.
02
Drugs
ALN-APOC3
03
Conditions
dyslipidemia
Beyond the preview
Go deeper on NCT06784349.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06784349.